Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

The company behind KitKat has launched a protein drink that it claims suppresses appetite in the same way as popular ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

Dieting for weight loss has long survived scientific criticism. But GLP-1 medicines may be the final nail in the coffin of ...

Statements by Robert F. Kennedy Jr. and Elon Musk tap into a dispute over whether lifestyle changes or drugs are a better way to treat obesity.